Principal-Agent Hypothesis Testing

Consider the relationship between a regulator (the principal) and an experimenter (the agent) such as a pharmaceutical company. The pharmaceutical company wishes to sell a drug for profit, whereas the regulator wishes to allow only efficacious drugs to be marketed. The efficacy of the drug is not known to the regulator, so the pharmaceutical company must run a costly trial to prove efficacy to the regulator. Critically, the statistical protocol used to establish efficacy affects the behavior of a strategic, self-interested agent; a lower standard of statistical evidence incentivizes the agent to run more trials that are less likely to be effective. The interaction between the statistical protocol and the incentives of the pharmaceutical company is crucial for understanding this system and designing protocols with high social utility. In this work, we discuss how the regulator can set up a protocol with payoffs based on statistical evidence. In particular, we study a setting where the regulator can limit the profit of the company, and show that the optimal protocols are instances of e-values, shedding new light on this statistical tool.

Authors

Institutions

Publication Details

Journal
Journal of the American Statistical Association
Published
2026-08-27
DOI
https://doi.org/10.1080/01621459.2026.2724031
Citations
4
Primary Topic
Game Theory and Applications
Type
article
Field-Weighted Citation Impact
9.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Principal-Agent Hypothesis Testing

Jake A. Soloff, Michael I. Jordan, Stephen Bates, Michael C. Sklar
4 citations
Journal of the American Statistical Association
Game Theory and Applications
9.88
article

Principal-Agent Hypothesis Testing

Jake A. Soloff, Michael I. Jordan, Stephen Bates, Michael C. Sklar
article en
4 citations

Abstract

Consider the relationship between a regulator (the principal) and an experimenter (the agent) such as a pharmaceutical company. The pharmaceutical company wishes to sell a drug for profit, whereas the regulator wishes to allow only efficacious drugs to be marketed. The efficacy of the drug is not known to the regulator, so the pharmaceutical company must run a costly trial to prove efficacy to the regulator. Critically, the statistical protocol used to establish efficacy affects the behavior of a strategic, self-interested agent; a lower standard of statistical evidence incentivizes the agent to run more trials that are less likely to be effective. The interaction between the statistical protocol and the incentives of the pharmaceutical company is crucial for understanding this system and designing protocols with high social utility. In this work, we discuss how the regulator can set up a protocol with payoffs based on statistical evidence. In particular, we study a setting where the regulator can limit the profit of the company, and show that the optimal protocols are instances of e-values, shedding new light on this statistical tool.

Journal of the American Statistical Association
University of Michigan (US), IEC University (IN), Fleet Community Hospital (GB), Massachusetts Institute of Technology (US)
European Commission
Partnerships for the goals
Openalex Percentile: Top 6%
Game Theory and Applications
9.88
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.